1. Home
  2. FBIOP
  3. FBIOP News

Latest Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) News on May 24, 2024

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

GlobeNewswire

8 days ago

Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

Associated Press Finance

9 days ago

Fortress Biotech: Q1 Earnings Snapshot

Business Wire

4 months ago

Issue of Debt

Share on Social Networks: